for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Almirall SA

ALM.MC

Latest Trade

16.61EUR

Change

0.06(+0.36%)

Volume

112,812

Today's Range

16.42

 - 

16.83

52 Week Range

12.88

 - 

18.14

As of on the Mercado Continuo Espana ∙ Minimum 15 minute delay

Pricing

Previous Close
16.55
Open
16.47
Volume
112,812
3M AVG Volume
3.19
Today's High
16.83
Today's Low
16.42
52 Week High
18.14
52 Week Low
12.88
Shares Out (MIL)
174.55
Market Cap (MIL)
2,881.90
Forward P/E
20.25
Dividend (Yield %)
1.23

Next Event

Q3 2019 Almirall SA Earnings Release

Latest Developments

More

Almirall Appoints Mike McClellan As New CFO

Almirall H1 Net Profit Up At 61.9 Mln Euros YoY

Almirall Exercises Its Option With Dermira To License Rights To Lebrikizumab In Europe For Atopic Dermatitis

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Almirall SA

Almirall SA is a Spain-based company principally engaged in the pharmaceuticals manufacture. The Company focuses on development and marketing of drugs applied in various therapeutic areas, such as nervous system, gastrointestinal, dermatological, respiratory system, antiinfectives, as well as antineoplastic and immunomodulating agents. The Company's activities are divided into four business segments: Own network, which focuses on the commercialization of pharmaceuticals through own brand names; Licenses, which sells product rights to third parties; Research and development (R&D), which is responsible for the creation of drug candidates, as well as Dermatology, which includes sale of dermatological medicines in the United States. The Company operates through numerous subsidiaries in Europe, the Americas, Africa, Asia and Australia.

Industry

Major Drugs

Contact Info

Ronda General Mitre, 151

+34.932.913000

https://www.almirall.es/

Executive Leadership

Jorge Gallardo Ballart

Chairman of the Board

Peter Guenter

Chief Executive Officer

Daniel Bravo Andreu

Second Vice Chairman of the Board

David Nieto

Chief Financial Officer, Executive Vice President - Finance

Bhushan Hardas

Chief Scientific Officer y Executive Vice President Research and Development

Key Stats

2.36 mean rating - 11 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2016

0.8K

2017

0.6K

2018

0.8K

2019(E)

0.9K
EPS (EUR)

2016

0.474

2017

0.158

2018

0.503

2019(E)

0.816
Price To Earnings (TTM)
34.63
Price To Sales (TTM)
3.51
Price To Book (MRQ)
2.34
Price To Cash Flow (TTM)
27.51
Total Debt To Equity (MRQ)
42.72
LT Debt To Equity (MRQ)
41.88
Return on Investment (TTM)
4.57
Return on Equity (TTM)
3.92

Latest News

Latest News

BRIEF-Almirall To Pay Scrip Dividend Of 0.198 Euros Gross/Right

* SAID ON WEDNESDAY IT WOULD INCREASE SHARE CAPITAL BY ISSUING 2.3 MILLION SHARES FOR ITS SCRIP DIVIDEND PROGRAM

BRIEF-Almirall: NICE In UK Gives Final Recommendation For Co's Drug To Treat Plaque Psoriasis

* SAID ON WEDNESDAY THAT NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) IN UK HAD PUBLISHED ITS FINAL RECOMMENDATION FOR ILUMETRI (TILDRAKIZUMAB) AS A COST-EFFECTIVE OPTION TO TREAT MODERATE-TO-SEVERE PLAQUE PSORIASIS

Spain's Almirall bets on dermatology with $650 million U.S. deal

Spanish pharmaceutical company Almirall <ALM.MC> said on Friday it had agreed to buy five dermatology brands from U.S. company Allergan <AGN.N> for up to $650 million in cash.

Spain's Almirall to buy U.S. dermatology portfolio from Allergan

Spanish pharmaceutical company Almirall SA said on Friday it has agreed to buy a portfolio of five brands from U.S. firm Allergan for up to $650 million in cash.

BRIEF-Almirall Sees 20 Pct EBITDA Growth In 2018

* FY EBITDA 142.2 MILLION EUROS VERSUS 227.6 MILLION EUROS YEAR AGO

BRIEF-Almirall FY Net Result Turns To Loss Of 304 Million Euros

* FY NET LOSS 304.0 MILLION EUROS VERSUS PROFIT OF 75.5 MILLION EUROS YEAR AGO

BRIEF-Almirall Signs Distribution Agreement With AstraZeneca For Crestor And Provisacor In Spain

* EXECUTES LICENSE AND SUPPLY AGREEMENT WITH ASTRAZENECA FOR CRESTOR AND PROVISACOR (ROSUVASTATIN)

BRIEF-Almirall And Athenex Announces Partnership For Treatment Of Actinic Keratosis

* ALMIRALL AND ATHENEX ANNOUNCE STRATEGIC PARTNERSHIP FOR THE TREATMENT OF ACTINIC KERATOSIS

BRIEF-Almirall Announces Positive Top-Line Results From ASCENT Trial For Tudorza

* ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE IV ASCENT TRIAL FOR TUDORZA

BRIEF-Almirall announces achievement of $80 mln sales-related milestones from agreement with Astrazeneca

* ANNOUNCES ACHIEVEMENT OF $80 MILLION SALES-RELATED MILESTONES FROM AGREEMENT WITH ASTRAZENECA Source text for Eikon:

Spain's Almirall warns of delay in approval for psoriasis drug

Spanish pharma company Almirall said on Tuesday it expects the launch of psoriasis treatment drug, Tildrakizumab, in Europe to get delayed by at least six months due to regulatory hurdles.

BRIEF-Almirall 9-month net result turns to loss of 99.7 mln euros YoY

* 9-MONTH EBITDA 100.1 MILLION EUROS VERSUS 183.8 MILLION EUROS YEAR AGO

BRIEF-Almirall ends phase III research for nail psoriasis product in Europe

* TERMINATES ITS RESEARCH ACTIVITIES FOR P3073 PROGRAM (NAIL PSORIASIS) IN EUROPE IN PHASE III OF DEVELOPMENT Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Almirall: study confirms efficacy of Sativex in treating multiple sclerosis spasticity

* SAYS STUDY CONFIRMS EFFICACY AND TOLERABILITY OF SATIVEX IN TREATMENT OF MULTIPLE SCLEROSIS SPASTICITY RESISTANT PATIENTS Source text: http://bit.ly/2yPWT4P Further company coverage: (Gdynia Newsroom)

BRIEF-Almirall ends research for two products in US

* SAYS DECIDED TO TERMINATE ITS RESEARCH ACTIVITIES FOR P3058 (ONYCHOMYCOSIS) AND P3073 (NAIL PSORIASIS) IN THE US

BRIEF-Almirall announces phase III positive Duaklir results for COPD

* SAYS PHASE III STUDY SHOWS DUAKLIR SIGNIFICANTLY IMPROVES LUNG FUNCTION IN MODERATE TO VERY SEVERE STABLE COPD

BRIEF-Almirall board approves appointment of Peter Guenter as new CEO

* BOARD APPROVES APPOINTMENT OF PETER GUENTER AS CEO EFFECTIVE OCT. 1 FOLLOWING SUCCESSION PLAN INITIATED MORE THAN A YEAR AGO Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Almirall appoints Ron Menezes as President and General Manager of Aqua Pharmaceuticals

* NAMES RON MENEZES AS PRESIDENT AND GENERAL MANAGER OF AQUA PHARMACEUTICALS Further company coverage: (Gdynia Newsroom)

BRIEF-Almirall H1 EBITDA down 52.6 pct at 58.6 mln euros YoY

* H1 EBITDA DOWN 52.6 PERCENT AT 58.6 MILLION EUROS VERSUS YEAR AGO

BRIEF-Almirall H1 net result turns to loss of 73.1 mln euros

* H1 NET LOSS 73.1 MILLION EUROS VERSUS PROFIT 80.5 MILLION EUROS YEAR AGO

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up